Professional Media briefs: March 2013

Sharon Spector
Sharon Spector

Current Psychiatry has a new publisher: Sharon Spector, who has been with the publication since its launch 10 years ago. Spector was previously director of sales, responsible for several titles. She will now focus on Current Psychiatry and oversee the publication's website, which goes live in the second half of 2013.

BioMed Central launched the Journal of Eating Disorders, which the publisher called the “first open-access journal of its kind.” The publication is co-edited by Phillipa Hay of the University of Western Sidney and ­Stephen Touyez of the University of Sydney.

Elsevier launched the Association for Contextual Behavioral Science's Journal of ­Behavioral Sciences. “It has been a long time in the making,” ACBS president-elect Sonja ­Batten said in a statement. The first issue printed in December.

Wiley and the nonprofit Cochrane Collaboration have renewed their decade-old partnership to publish the Cochrane Library's reviews of healthcare and policy. The agreement includes a provision to make all systematic reviews published as of February 2013 available through an open-access channel one year after Cochrane Library publication.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.